Boston Scientific Corporation
BSX
$73.85
-$2.37-3.11%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 56.40% | 55.66% | 37.04% | 14.54% | 16.32% |
| Total Depreciation and Amortization | 7.80% | 9.48% | 7.08% | 6.17% | 6.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.68% | -25.40% | -44.81% | 85.56% | 60.12% |
| Change in Net Operating Assets | 46.75% | 90.87% | 103.80% | 59.90% | 40.00% |
| Cash from Operations | 31.99% | 57.56% | 62.80% | 53.90% | 37.24% |
| Capital Expenditure | -10.89% | -2.82% | -1.14% | -2.44% | -11.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 65.67% | -144.27% | -552.36% | -225.83% | -156.21% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.46% | 55.19% | -28.13% | -138.60% | -358.93% |
| Cash from Investing | 53.58% | -92.09% | -274.14% | -148.51% | -120.94% |
| Total Debt Issued | -33.19% | -18.65% | -17.22% | -18.65% | -- |
| Total Debt Repaid | -287.33% | -247.83% | -204.88% | -145.97% | -13,125.00% |
| Issuance of Common Stock | 22.61% | 32.42% | 36.87% | 33.17% | 26.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 15.07% | 12.73% | -85.91% | -43.51% | -51.03% |
| Cash from Financing | -121.78% | -99.81% | -92.98% | -70.91% | 36,180.00% |
| Foreign Exchange rate Adjustments | 481.82% | 1,400.00% | 522.22% | 418.18% | -175.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | -- | -- |
| Net Change in Cash | 442.44% | -177.39% | -195.05% | -191.00% | -542.86% |